Finall Exam:l NRl 567/l NR567l (Latestl
2026/l 2027l Update)l Advancedl
Pharmacologyl forl thel AGACNPl Guidel
|Q/Al |l Gradel A|l 100%l Correctl (Verifiedl
Answers)l -Chamberlain
Q:l Nonergotl Derivativesl (Dopaminel Agonists):l Prototype
Answer:
pramipexole
Q:l pramipexole:l MOA
Answer:
stimulatingl dopamine-2l andl dopamine-3l receptorsl inl thel brain.l Helpsl compensatel forl thel
decreasedl dopaminel levelsl inl thel brainl ofl patientsl withl Parkinson's,l leadingl tol improvedl
motorl function.
Q:l pramipexole:l Sidel effects
Answer:
Impulsel controll disordersl
problemsl withl sleepl
GIl effectsl -l nauseal andl constipationl
CNSl effectsl -l dizzinessl andl hallucinations
Orthostaticl hypotensionl
dyskinesiasl canl occurl inl highl doses
,Q:l pramipexole:l Labsl tol Monitor
Answer:
BMPl -l renall functionl (excretedl here)
Q:l Ergotl Derivatices:l Prototype
Answer:
bromocriptine
Q:l bromocriptine:l MOA
Answer:
stimulatesl dopaminel receptorsl throughl directl activationl therebyl addingl tol thel effectsl ofl
dopaminel derivedl froml levodopa
Q:l bromocriptine:l sidel effects
Answer:
GIl effects:l nausea
CNSl effects:l confusion,l nightmares,l agitations,l hallucinations,l andl paranoidl delusions
Dyskinesiasl canl occurl
posturall hypotensionl
rarely,l butl canl causel pulmonaryl infiltrates.
Q:l COMTl Inhibitors:l Prototype
Answer:
,entacapone
Q:l entacapone:l MOA
Answer:
Itl enhancesl thel effectl ofl levodopal byl inhibitingl itsl metabolisml inl thel intestinel andl
peripherall tissues.l Thisl actionl prolongsl thel half-lifel ofl levodopal andl increasesl itsl
availabilityl byl decreasingl thel productionl ofl levodopal metabolitesl thatl competel withl
levodopal forl transportl acrossl thel blood-brainl barrier.
Q:l entacapone:l sidel effects
Answer:
Dyskinesial
orthostaticl hypotensionl
N/V/D/Constipation
hallucinations/insomnia
behaviorall changesl
discolorationl ofl bodyl fluids
Q:l MAO-Bl Inhibitors:l Prototype
Answer:
selegiline
Q:l selegiline:l MOA
Answer:
Thesel medicationsl selectivelyl andl irreversiblyl inhibitl monoaminel oxidase-Bl (MAO-B),l
thel enzymel responsiblel forl thel inactivationl ofl dopaminel inl thel brain.l Thisl inhibitionl
, increasesl thel availabilityl ofl dopamine,l enhancingl dopaminergicl neurotransmissionl andl
alleviatingl symptomsl ofl Parkinson'sl disease.
Q:l selegiline:l sidel effects
Answer:
CNSl -l agitation,l confusion,l dizziness,l orl hallucinations.l
orthostaticl hypotension,l atl highl dosesl mayl causel hypertensionl
nausea
Q:l Dopaminel Releaser:l Prototype
Answer:
amantadine
Q:l amantadine:l MOA
Answer:
Itl worksl primarilyl byl increasingl dopaminel synthesis,l release,l orl reuptake.
Q:l amantadine:l sidel effects
Answer:
CNSl -l confusion,l lightheadedness,l anxietyl
Anticholinergicl effectsl -l dryl mouth,l constipation,l blurredl visionl urinaryl retention
Livedol Reticularisl -l mottledl skinl discoloration
Q:l Cholinesterasel Inhibitors:l Prototype
2026/l 2027l Update)l Advancedl
Pharmacologyl forl thel AGACNPl Guidel
|Q/Al |l Gradel A|l 100%l Correctl (Verifiedl
Answers)l -Chamberlain
Q:l Nonergotl Derivativesl (Dopaminel Agonists):l Prototype
Answer:
pramipexole
Q:l pramipexole:l MOA
Answer:
stimulatingl dopamine-2l andl dopamine-3l receptorsl inl thel brain.l Helpsl compensatel forl thel
decreasedl dopaminel levelsl inl thel brainl ofl patientsl withl Parkinson's,l leadingl tol improvedl
motorl function.
Q:l pramipexole:l Sidel effects
Answer:
Impulsel controll disordersl
problemsl withl sleepl
GIl effectsl -l nauseal andl constipationl
CNSl effectsl -l dizzinessl andl hallucinations
Orthostaticl hypotensionl
dyskinesiasl canl occurl inl highl doses
,Q:l pramipexole:l Labsl tol Monitor
Answer:
BMPl -l renall functionl (excretedl here)
Q:l Ergotl Derivatices:l Prototype
Answer:
bromocriptine
Q:l bromocriptine:l MOA
Answer:
stimulatesl dopaminel receptorsl throughl directl activationl therebyl addingl tol thel effectsl ofl
dopaminel derivedl froml levodopa
Q:l bromocriptine:l sidel effects
Answer:
GIl effects:l nausea
CNSl effects:l confusion,l nightmares,l agitations,l hallucinations,l andl paranoidl delusions
Dyskinesiasl canl occurl
posturall hypotensionl
rarely,l butl canl causel pulmonaryl infiltrates.
Q:l COMTl Inhibitors:l Prototype
Answer:
,entacapone
Q:l entacapone:l MOA
Answer:
Itl enhancesl thel effectl ofl levodopal byl inhibitingl itsl metabolisml inl thel intestinel andl
peripherall tissues.l Thisl actionl prolongsl thel half-lifel ofl levodopal andl increasesl itsl
availabilityl byl decreasingl thel productionl ofl levodopal metabolitesl thatl competel withl
levodopal forl transportl acrossl thel blood-brainl barrier.
Q:l entacapone:l sidel effects
Answer:
Dyskinesial
orthostaticl hypotensionl
N/V/D/Constipation
hallucinations/insomnia
behaviorall changesl
discolorationl ofl bodyl fluids
Q:l MAO-Bl Inhibitors:l Prototype
Answer:
selegiline
Q:l selegiline:l MOA
Answer:
Thesel medicationsl selectivelyl andl irreversiblyl inhibitl monoaminel oxidase-Bl (MAO-B),l
thel enzymel responsiblel forl thel inactivationl ofl dopaminel inl thel brain.l Thisl inhibitionl
, increasesl thel availabilityl ofl dopamine,l enhancingl dopaminergicl neurotransmissionl andl
alleviatingl symptomsl ofl Parkinson'sl disease.
Q:l selegiline:l sidel effects
Answer:
CNSl -l agitation,l confusion,l dizziness,l orl hallucinations.l
orthostaticl hypotension,l atl highl dosesl mayl causel hypertensionl
nausea
Q:l Dopaminel Releaser:l Prototype
Answer:
amantadine
Q:l amantadine:l MOA
Answer:
Itl worksl primarilyl byl increasingl dopaminel synthesis,l release,l orl reuptake.
Q:l amantadine:l sidel effects
Answer:
CNSl -l confusion,l lightheadedness,l anxietyl
Anticholinergicl effectsl -l dryl mouth,l constipation,l blurredl visionl urinaryl retention
Livedol Reticularisl -l mottledl skinl discoloration
Q:l Cholinesterasel Inhibitors:l Prototype
